U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C25H39NO3
Molecular Weight 401.5821
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CETILISTAT

SMILES

CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1

InChI

InChIKey=MVCQKIKWYUURMU-UHFFFAOYSA-N
InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3

HIDE SMILES / InChI

Description

Cetilistat (ATL-962) is a pancreatic lipase inhibitor, which was developed by Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd for the potential treatment of obesity in patients with or without diabetes. This drug was approved for using in Japan

Originator

Alizyme
1

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Pancreatic lipase
5
Inhibitor
8,504
 5.95 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Obesity
206
 Primary
Approved
8,583
Unknown

PubMed

Patents

06624161
1
07396952
1
07825113
1
07858617
1
20020018812
2
JP2010254623A
1

Sample Use Guides

In Vivo Use Guide
60 mg three times daily t.i.d., 120 mg t.i.d. and 240 mg t.i.d.
Route of Administration: Oral
In Vitro Use Guide
Unknown
ACTIVE MOIETY
Structure of CETILISTAT
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966